Forendo Pharma, a Turku, Finland-based clinical stage drug development company focusing on novel treatments in women’s health, received a €5 million investment from Sunstone Life Science Ventures.
Sunstone joined the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital III. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors.
The new financing will enable the company to progress its lead endometriosis program, FOR-6219, an oral small molecule HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year.
Founded in 2013 by academic endocrinology experts and Finnish drug development pioneers and led by Risto Lammintausta, CEO, Forendo Pharma is a drug development company, with core competences in modulating tissue specific hormone mechanisms. Its pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; inhibitor of another enzyme from the HSD17B family for the treatment of undisclosed gynecological condition (discovery); and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions.
FinSMEs
23/07/2019